FDA Turns Down F2G’s Antifungal, But Firm Plots Comeback As Trial Completes Accrual

 
• By Alaric DeArment
  
F2G plans to give its NDS for antifungal drug olorofim another shot • Source: Shutterstock

More from New Products

More from Scrip